141 related articles for article (PubMed ID: 12659890)
21. Electrochemical reduction of meloxicam at mercury electrode and its determination in tablets.
Beltagi AM; Ghoneim MM; Radi A
J Pharm Biomed Anal; 2002 Feb; 27(5):795-801. PubMed ID: 11814720
[TBL] [Abstract][Full Text] [Related]
22. Interaction of piroxicam with micelles: effect of hydrophobic chain length on structural switchover.
Chakraborty H; Sarkar M
Biophys Chem; 2005 Aug; 117(1):79-85. PubMed ID: 15908103
[TBL] [Abstract][Full Text] [Related]
23. Binding of Cu(II) complexes of oxicam NSAIDs to alternating AT and homopolymeric AT sequences: differential response to variation in backbone structure.
Chakraborty S; Sehanobish E; Sarkar M
J Biol Inorg Chem; 2012 Mar; 17(3):475-87. PubMed ID: 22270943
[TBL] [Abstract][Full Text] [Related]
24. Scavenging of photogenerated ROS by Oxicams. Possible biological and environmental implications.
Ferrari GV; Natera J; Paulina Montaña M; Muñoz V; Gutiérrez EL; Massad W; Miskoski S; García NA
J Photochem Photobiol B; 2015 Dec; 153():233-9. PubMed ID: 26453988
[TBL] [Abstract][Full Text] [Related]
25. Extended Hansen's solubility approach: meloxicam in individual solvents.
Babu PR; Subrahmanyam CV; Thimmasetty J; Manavalan R; Valliappan K
Pak J Pharm Sci; 2007 Oct; 20(4):311-6. PubMed ID: 17604255
[TBL] [Abstract][Full Text] [Related]
26. Determination of pKa values of nonsteroidal antiinflammatory drug-oxicams by RP-HPLC and their analysis in pharmaceutical dosage forms.
Demiralay EC; Alsancak G; Ozkan SA
J Sep Sci; 2009 Sep; 32(17):2928-36. PubMed ID: 19662642
[TBL] [Abstract][Full Text] [Related]
27. Indirect flow-injection spectrophotometric determination of meloxicam, tenoxicam and piroxicam in pharmaceutical formulations.
Al-Momani IF
Anal Sci; 2006 Dec; 22(12):1611-4. PubMed ID: 17159326
[TBL] [Abstract][Full Text] [Related]
28. Membrane fusion: a new function of non steroidal anti-inflammatory drugs.
Chakraborty H; Mondal S; Sarkar M
Biophys Chem; 2008 Sep; 137(1):28-34. PubMed ID: 18617319
[TBL] [Abstract][Full Text] [Related]
29. Unusual coordinating behavior by three non-steroidal anti-inflammatory drugs from the oxicam family towards copper(II). Synthesis, X-ray structure for copper(II)-isoxicam, -meloxicam and -cinnoxicam-derivative complexes, and cytotoxic activity for a copper(II)-piroxicam complex.
Cini R; Tamasi G; Defazio S; Hursthouse MB
J Inorg Biochem; 2007 Aug; 101(8):1140-52. PubMed ID: 17592742
[TBL] [Abstract][Full Text] [Related]
30. [Possibilities of individual choice of NSAIDs on the example of the oxicam class, taking into account clinical and pharmacological characteristics].
Putilina MV; Teplova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7):36-41. PubMed ID: 35904290
[TBL] [Abstract][Full Text] [Related]
31. Modulation of non steroidal anti-inflammatory drug induced membrane fusion by copper coordination of these drugs: anchoring effect.
Majumdar A; Chakraborty S; Sarkar M
J Phys Chem B; 2014 Dec; 118(48):13785-99. PubMed ID: 25380501
[TBL] [Abstract][Full Text] [Related]
32. Formulation of meloxicam gel for topical application: In vitro and in vivo evaluation.
Bachhav YG; Patravale VB
Acta Pharm; 2010 Jun; 60(2):153-63. PubMed ID: 21134852
[TBL] [Abstract][Full Text] [Related]
33. Polarographic behaviour of meloxicam and its determination in tablet preparations and spiked plasma.
Altinöz S; Nemutlu E; Kir S
Farmaco; 2002 Jun; 57(6):463-8. PubMed ID: 12088061
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
Olkkola KT; Brunetto AV; Mattila MJ
Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
[TBL] [Abstract][Full Text] [Related]
35. Flow-injection analysis for meloxicam based on tris(2,2'-bipyridine) ruthenium(II)-Ce(IV) chemiluminescent system.
Ye H; Qiu B; Chen J; Lin J; Chen G
Luminescence; 2009; 24(4):260-5. PubMed ID: 19294660
[TBL] [Abstract][Full Text] [Related]
36. Host-guest complexation of oxicam NSAIDs with beta-cyclodextrin.
Banerjee R; Chakraborty H; Sarkar M
Biopolymers; 2004 Nov; 75(4):355-65. PubMed ID: 15372483
[TBL] [Abstract][Full Text] [Related]
37. Enzymatic probing of model lipid membranes: phospholipase A2 activity toward monolayers modified by oxicam NSAIDs.
Czapla K; Korchowiec B; Orlof M; Magnieto JR; Rogalska E
J Phys Chem B; 2011 Jul; 115(29):9290-8. PubMed ID: 21682312
[TBL] [Abstract][Full Text] [Related]
38. Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam.
Ambrus R; Kocbek P; Kristl J; Sibanc R; Rajkó R; Szabó-Révész P
Int J Pharm; 2009 Nov; 381(2):153-9. PubMed ID: 19616609
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous determination of piroxicam, meloxicam and tenoxicam in human plasma by liquid chromatography with tandem mass spectrometry.
Ji HY; Lee HW; Kim YH; Jeong DW; Lee HS
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Nov; 826(1-2):214-9. PubMed ID: 16169293
[TBL] [Abstract][Full Text] [Related]
40. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam.
Tavakoli M
Pharmacoeconomics; 2003; 21(6):443-54. PubMed ID: 12678570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
